CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.

Published

Journal Article (Review)

Cancer vaccines have demonstrated clinical benefit, however greater efficacy could be achieved by enhancing their immunogenicity. Owing to cancer vaccines depending on uptake and cross-presentation of tumor antigens by antigen-presenting cells (APCs), we hypothesized that greater immunogenicity would accompany strategies that direct antigen to APC-expressed mannose receptors, initiating a pathway increasing class I and II presentation to T cells. CDX-1307 consists of a human monoclonal antibody targeting the mannose receptor, fused to the human chorionic gonadotropin-β chain (hCG-β), a tumor antigen frequently expressed by epithelial cancers including bladder cancer. In Phase I studies of cancer patients, CDX-1307 was well tolerated and induced significant hCG-β-specific cellular and humoral immune responses when co-administered with GM-CSF and the Toll-like receptor agonists resiquimod and poly-ICLC. An ongoing Phase II trial evaluates CDX-1307 in patients with newly diagnosed, resectable, hCG-β-expressing bladder cancer, where low tumor burden and early intervention may provide greater potential for benefit.

Full Text

Duke Authors

Cited Authors

  • Morse, MA; Bradley, DA; Keler, T; Laliberte, RJ; Green, JA; Davis, TA; Inman, BA

Published Date

  • June 2011

Published In

Volume / Issue

  • 10 / 6

Start / End Page

  • 733 - 742

PubMed ID

  • 21692696

Pubmed Central ID

  • 21692696

Electronic International Standard Serial Number (EISSN)

  • 1744-8395

International Standard Serial Number (ISSN)

  • 1476-0584

Digital Object Identifier (DOI)

  • 10.1586/erv.11.20

Language

  • eng